newsfilter
← Latest News
GlobeNewswire·

Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock

NEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for